| Abstract | The inv(16)(p13q22) is found in de novo AML and is closely associated with the FAB subtype M4eo. The inv(16) is rarely reported in therapy-related AML (t-AML) patients. Herein, we report a case of t-AML with inv(16) after combination chemotherapy using antimitotic agent and alkylating agent (cis-platin-paclitaxel) for ovarian serous cystadenocarcinoma. |
| Authors | So-Young Lee, Myungshin Kim, Jihyang Lim, Yonggoo Kim, Kyungja Han, Sung Yong Kim, Hee Je Kim, In-Yang Park
(Affiliation: Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.)
|
| Journal | The Korean journal of laboratory medicine
(Korean J Lab Med)
Vol. 27
Issue 1
Pg. 19-21
(Feb 2007)
ISSN: 1598-6535 Korea (South) |
| PMID | 18094545
(Publication Type: Case Reports, English Abstract, Journal Article)
|
| Chemical References |
- Antimitotic Agents
- TP protocol
- Taxoids
- Cisplatin
|
| Topics |
- Antimitotic Agents
(adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Chromosomes, Human, Pair 16
(genetics)
- Cisplatin
(adverse effects, therapeutic use)
- Female
- Humans
- Inversion, Chromosome
- Leukemia, Myeloid, Acute
(chemically induced, pathology)
- Middle Aged
- Taxoids
(adverse effects, therapeutic use)
|
